Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a series of strategic updates aimed at sharpening its development priorities and extending its financial runway. The biotechnology company has executed …
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus Read More